Model development and in vivo screening of antivirals directed against Bunyavirales - Rift Valley Fever virus
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $3,000,000 to $7,000,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Points of contact
-
- Addison Miller addison.miller@nih.gov (301) 761-6791
- William Florence clint.florence@nih.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
Forecast text
The activity to be supported under this task order is the preliminary testing and evaluation of candidate therapies against viral pathogens of pandemic potential in relevant small animal models. The intent of this task order is to provide an initial demonstration of therapeutic efficacy against challenge with live viruses. This task will have the capability to provide some of the early testing required to support FDA approval of potential prevention or treatments for these viral infections. The data obtained from all of these studies will be used to prioritize compounds for further in vivo testing in larger animal models and/or further investigations. The viral families in which the government requires antiviral drug screening are those Bunyavirales which have pandemic potential.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast